Epigenetic Reprogramming — Biological Age Reversal Without Identity Loss

The claim has not been satisfied in humans. Partial epigenetic reprogramming without loss of cellular identity has been demonstrated in multiple mouse models and is extending toward non-human primates. No human clinical trials have been initiated. The biological mechanism is well-established: OSKM and related factors can reset epigenetic age marks; partial expression can do so without completing dedifferentiation; and the process produces functional improvements in at least some mouse tissues. The claim's human clinical evidence gap remains complete: no partial reprogramming therapy has yet entered a human trial. The pressure state is ESCALATING: the mechanism is well established across multiple mouse models and the field is heavily capitalised (INST-003), but whether partial reprogramming is safe and effective in humans — and whether epigenetic clock reversal constitutes genuine rejuvenation rather than a movable measurement (BN-001) — remains entirely untested outside model organisms.

The human clinical evidence gap that AS-001 identified as complete is now closing. Life Biosciences has received FDA IND clearance for ER-100, a partial OSK reprogramming therapy, with a stated trial start of Q1 2026 — the first human trial of any partial epigenetic reprogramming therapy. This is the first half of AT-001's named resolution attractor ("first human safety data and validated functional outcome biomarkers"); the second half — actual safety and clock-reversal data — does not yet exist, since the trial has only just been cleared to begin, not completed or reported. The pressure state remains ESCALATING rather than moving to RESOLVING: clearance to run a trial is a regulatory and operational milestone, not efficacy or safety evidence. BN-001 (clock validity as a rejuvenation surrogate) is unaffected by this development and remains the record's primary interior bottleneck regardless of how the ER-100 trial proceeds. This assessment exists to record that the record's own named attractor condition has begun to materialise, not to anticipate its outcome.